FGF19 can act against obesity-induced muscle atrophy, metabolic derangement, and abnormal irisin secretion by promoting PGC-1α and FNDC5 expression (Guo et al., 2021). The gene discussed is PPARGC1A; the disease is obesity due to melanocortin 4 receptor deficiency.